arGen-X Raises $37 Million To Advance Its Human Antibodies Into The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.